• TRADJENTA (TRAGENTA) 5mg 30 tablets

Buy Tradjenta (aka Tragenta or Trajenta) 5mg 30 tablets

      Active ingredient: linagliptin

Free Shipping
Without prescription
1 box x 30 tablets x 5mg

Short description

Oral hypoglycemic drug. Linagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which is involved in the inactivation of incretin hormones - type 1 glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are rapidly destroyed by the DPP-4 enzyme. Both incretins are involved in maintaining glucose concentrations at the physiological level. Basal concentrations of GLP-1 and GIP are low during the day, but quickly increase in response to food intake. GLP-1 and GIP increase insulin biosynthesis and its secretion by β-cells of the pancreas at normal or increased blood glucose concentration. In addition, GLP-1 reduces the secretion of glucagon by the α-cells of the pancreas, which leads to a decrease in glucose production in the liver.

Indications for use

Type 2 diabetes mellitus:

as monotherapy in patients with inadequate glycemic control only on the background of diet and exercise, with metformin intolerance or with contraindications to its use due to renal failure;

as a two-component combination therapy with metformin, sulfonylurea derivatives or thiazolidinedione in case of ineffectiveness of diet therapy, exercise and monotherapy with these drugs;

as a three-component combination therapy with metformin and sulfonylurea derivatives in case of ineffectiveness of diet therapy, exercise and combination therapy with these drugs;

as a two-component combination therapy with insulin or multi-component therapy with insulin, metformin and / or pioglitazone and / or sulfonylurea derivatives in case of ineffectiveness of diet therapy, exercise and combination therapy with these drugs.

Contraindications for use

  • type 1 diabetes mellitus;
  • diabetic ketoacidosis;
  • pregnancy;
  • lactation period (breastfeeding);
  • children and adolescents up to 18 years old;
  • hypersensitivity to any component of the drug.


Use during pregnancy and for children

The use of linagliptin during pregnancy and during breastfeeding is contraindicated.

Data obtained in preclinical studies in animals indicate the release of linagliptin and its metabolite in breast milk. The risk of exposure to newborns and children during breastfeeding is not excluded.

If necessary, the use of linagliptin during lactation, breastfeeding should be discontinued.

The use of the drug is contraindicated in children and adolescents under 18 years of age.


Side effects

The following side effects have been observed with linagliptin monotherapy:


From the immune system: hypersensitivity reactions.


From the respiratory system: cough.


From the digestive system: pancreatitis.


Infectious diseases: nasopharyngitis.


When using linagliptin with metformin:


From the immune system: hypersensitivity reactions.


From the respiratory system: cough.


From the digestive system: pancreatitis.


Infectious diseases: nasopharyngitis.


When using linagliptin with sulfonylurea derivatives:


From the immune system: hypersensitivity reactions.


Metabolic disorders: hypertriglyceridemia.


From the respiratory system: cough.


From the digestive system: pancreatitis.


Infectious diseases: nasopharyngitis.


When using linagliptin with pioglitazone:


From the immune system: hypersensitivity reactions.


Metabolic disorders: hyperlipidemia.


From the respiratory system: cough.


From the digestive system: pancreatitis.


Infectious diseases: nasopharyngitis.


Others: weight gain.


When using linagliptin with insulin:


From the immune system: hypersensitivity reactions.


From the respiratory system: cough.


From the digestive system: pancreatitis, constipation.


Infectious diseases: nasopharyngitis.


When using linagliptin with metformin and sulfonylurea derivatives:


From the immune system: hypersensitivity.


Metabolic disorders: hypoglycemia.


From the respiratory system: cough.


From the digestive system: pancreatitis.


Infectious diseases: nasopharyngitis.


When using linagliptin with metformin and pioglitazone:


From the immune system: hypersensitivity reactions.


Metabolic disorders: hyperlipidemia.


From the respiratory system: cough.


From the digestive system: pancreatitis.


Infectious diseases: nasopharyngitis.


Others: weight gain.


Post-marketing experience of application:


From the immune system: angioedema, urticaria.


From the digestive system: acute pancreatitis.


On the part of the skin: rash.


Special instructions

Tradjenta is contraindicated in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

The incidence of hypoglycemia in the case of linagliptin monotherapy was comparable to placebo.

In clinical studies, it was reported that the incidence of hypoglycemia in the case of the use of linagliptin in combination with drugs that are not considered to cause hypoglycemia (metformin, thiazolidinedione derivatives) was similar to the corresponding effect of placebo.

Sulfonylurea derivatives are known to induce hypoglycemia. Therefore, in the case of using linagliptin in combination with sulfonylurea derivatives, caution should be exercised. If necessary, it is possible to reduce the dose of sulfonylurea derivatives.

Special clinical studies on the use of linagliptin in combination with insulin have not been conducted.

Linagliptin does not increase the risk of developing cardiovascular disease.

Linagliptin in combination therapy with other oral hypoglycemic drugs was used in patients with severe renal failure.

Linagliptin provided a significant decrease in glycosylated hemoglobin concentration and fasting glucose concentration.

No dose adjustment is required when used in patients with impaired renal and hepatic function and in elderly patients.

Influence on the ability to drive vehicles and mechanisms

Studies of the effect of Trajenta on the ability to drive vehicles and mechanisms have not been conducted. However, due to the possible development of dizziness, care must be taken when driving vehicles and mechanisms.

Tradjenta for sale: Even if a prescription is not required, it is assumed that you have a valid prescription or doctor's recommendation. Please do not self-cure. Get expert advice before ordering. 



The product is intended for Russian market and can be labeled in Russian (Packaging design may vary). With detailed English printed manual. 

Write a review

Note: HTML is not translated!
    Bad           Good

TRADJENTA (TRAGENTA) 5mg 30 tablets

  • Product Code: TR5-30
  • Availability: In Stock
  • $65.98

  • Ex Tax: $65.98